Targeting ubiquitination for cancer therapies

John Kenneth Morrow, Hui Kuan Lin, Shao Cong Sun, Shuxing Zhang

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations

Abstract

Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.

Original languageEnglish (US)
Pages (from-to)2333-2350
Number of pages18
JournalFuture Medicinal Chemistry
Volume7
Issue number17
DOIs
StatePublished - Nov 2015

Keywords

  • E3 ligase inhibition
  • SCF complex
  • Skp2 inhibitors
  • cancer therapeutics
  • deubiquitinase
  • high-throughput virtual screening
  • hot spots
  • in silico modeling
  • small molecule inhibitors
  • ubiquitination

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Targeting ubiquitination for cancer therapies'. Together they form a unique fingerprint.

Cite this